Wegovy and Zepbound, weight-loss drugs derived from GLP-1 receptor agonists, demonstrate significant effects beyond weight reduction. In a study that analyzed health records of over two million diabetic patients, researchers uncovered that these medications potentially reduce risks for various conditions, such as Alzheimer's and heart diseases. However, they also noted increased GI issues and low blood pressure among users. This evidence reinforces the beneficial role of treating obesity, as obesity itself is linked to numerous health concerns.
What this paper shows is that treating obesity and metabolic syndrome likely has a broad health profile, says Al-Aly.
The group found that people taking the GLP-1 medications had a lower risk of a number of health conditions, including Alzheimer's disease and dementia.
Collection
[
|
...
]